TGFB1 mRNA expression is associated with poor prognosis and specific features of inflammation in ccRCC

To determine whether TGFB1 affects the immune microenvironment of ccRCC, we investigated the association between TGFB1 expression and clinicopathological features. Tissue microarray was generated from 158 total or partial nephrectomy samples and 12 tumor-adjacent normal kidney tissue. TGFB1 expression was assessed by RNA in situ hybridization and quantified using ImageJ software. T GFB1 was significantly upregulated in ccRCC tissue than in normal kidney tissues ( P = 1.03 × 10 −9 ). Tumors with a high WHO/ISUP grade had higher TGFB1 expression levels ( P = 7.05 × 10 −3 ). Of 139 patients with localized ccRCC and whose follow-up data were available, those in the TGFB1 -high group displayed significantly shorter relapse-free survival than those in the TGFB1 -low group ( P = 0.0251). TGFB1 expression was significantly upregulated in patients who developed distant metastasis after surgery ( n = 12) than in patients without metastasis ( n = 127; P = 0.00167). TGFB1 expression positively correlated with the number of PD-L1-positive cells in the tumor stroma ( P = 0.0206, ρ = 0.163). Furthermore, TGFB1 expression was associated with the formation of tertiary lymphoid structures. TGF-β1 is a prognostic indicator of worse outcome for ccRCC and might be a therapeutic target in advanced ccRCC. Our data provide new insights into the association between tumor biology and tumor microenvironment in ccRCC.